Red MounTaiN
WellNess CeNTer
Expertise in
Hormone
Replacement
Therapy
certified by Institute for Functional Medicine
I wanted to share this information about the recent FDA updates to menopausal hormone therapy (HRT) labeling, which is the first major revision in over twenty years.
​
The FDA is removing some of the severe "black box" warnings from many estrogen and estrogen-progestogen therapies. These warnings, which were largely influenced by early interpretations of the Women’s Health Initiative (WHI) study in the early 2000s, often overstated risks for younger menopausal women.
This update brings long-overdue clarity and confidence back to hormone care. It confirms that HRT can be delivered safely, responsibly, and effectively when it is:
-
Personalized: Guided by comprehensive testing and tailored to the individual's biological and risk profile, using a root cause approach.
-
Thoughtfully Timed: Especially for women experiencing symptoms near the start of menopause or in the years shortly following menopause.
For many women who previously avoided discussing hormone therapy due to these past concerns, this is a great time to re-open the conversation.